Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceResearch in context

Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceResearch in context

Summary: Background: Tyrosine protein-kinase 2 (TYK2) mediates inflammatory signalling through multiple cytokines, including interferon-α (IFNα), interleukin (IL)-12, and IL-23. TYK2 missense mutations protect against type 1 diabetes (T1D), and inhibition of TYK2 shows promise in other autoimmune c...

Full description

Saved in:
Bibliographic Details
Main Authors: Farooq Syed, Olivia Ballew, Chih-Chun Lee, Jyoti Rana, Preethi Krishnan, Angela Castela, Staci A. Weaver, Namratha Shivani Chalasani, Sofia F. Thomaidou, Stephane Demine, Garrick Chang, Alexandra Coomans de Brachène, Maria Ines Alvelos, Eugenia Martin Vazquez, Lorella Marselli, Kara Orr, Jamie L. Felton, Jing Liu, John S. Kaddis, Piero Marchetti, Arnaud Zaldumbide, Donalyn Scheuner, Decio L. Eizirik, Carmella Evans-Molina
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:EBioMedicine
Subjects:
Type 1 diabetes
β cell
T cell
Islets of langerhans
Tyrosine protein-kinase 2 (TYK2)
Interferon-α
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396425001781
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary: Background: Tyrosine protein-kinase 2 (TYK2) mediates inflammatory signalling through multiple cytokines, including interferon-α (IFNα), interleukin (IL)-12, and IL-23. TYK2 missense mutations protect against type 1 diabetes (T1D), and inhibition of TYK2 shows promise in other autoimmune conditions. Methods: We evaluated the effects of specific TYK2 inhibitors (TYK2is) in pre-clinical models of T1D, including human β cells, cadaveric islets, iPSC-derived islets, and mouse models. Findings: In vitro studies showed that TYK2is prevented IFNα-induced β cell HLA class I up-regulation, endoplasmic reticulum stress, and chemokine production. In co-culture studies, pre-treatment of β cells with TYK2i prevented IFNα-induced antigenic peptide presentation and alloreactive and autoreactive T cell degranulation. In vivo administration of BMS-986202 in two mouse models of T1D (RIP-LCMV-GP and NOD mice) reduced systemic and tissue-localised inflammation, prevented β cell death, and delayed T1D onset. Transcriptional phenotyping of pancreatic islets, pancreatic lymph nodes, and spleen highlighted a role for TYK2 inhibition in modulating signalling pathways associated with inflammation, translational control, stress signalling, secretory function, immunity, and diabetes. Additionally, TYK2i treatment changed the composition of innate and adaptive immune cell populations in the blood and disease target tissues. Interpretation: These findings indicate that TYK2i has beneficial effects on both the immune and endocrine compartments in models of T1D, thus supporting a path forward for testing TYK2is in human T1D. Funding: This work was supported by the National Institutes of Health (NIH), Veteran Affairs (VA), Breakthrough T1D, and gifts from the Sigma Beta Sorority, the Ball Brothers Foundation, and the George and Frances Ball Foundation.
ISSN:2352-3964

Similar Items